Poolbeg Pharma plc
Director Dealing
25 June 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, confirms that as announced on 20 May 2025, Mr Cathal Friel, Executive Chair and PDMR of the Company, participated in the Fundraising subscribing for 4,000,000 new Ordinary Shares at a price of 2.5p per share (the Issue Price). Following the AGM earlier this week, the New Ordinary Shares issued pursuant to the Fundraising were admitted to trading at 8am today.
Following this transaction, Cathal Friel holds a total of 41,219,757 ordinary shares in the Company, representing approximately 5.91% of the Company's issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a. | Name of PDMR | Cathal Friel | |
| 2 | Reason for notification
| ||
| a. | Position/Status | Executive Chair | |
| b. | Initial notification/ Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a. | Name | Poolbeg Pharma plc | |
| b. | LEI | 213800UZ8WJLWYHBFL52 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a. | Description of the financial instrument, type of instrument
| Ordinary shares of 0.02 pence each
ISIN GB00BKPG7Z60 | |
| b. | Nature of the transaction | Purchase of ordinary shares in connection with the fundraising initially announced on 20 May 2025. | |
| c. | Price(s) and volume(s) | Price(s) | Volume(s) |
| 2.5p | 4,000,000 | ||
| d. | Aggregated information
- Aggregated Volume
- Price |
As in 4c) above
| |
| e. | Date of the transaction | 25 June 2025 | |
| f. | Place of the transaction | London Stock Exchange, AIM Market (XLON)
| |
Enquiries
| Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O'Connell, CFO
| +44 (0) 207 183 1499 ir@poolbegpharma.com |
| Cavendish Capital Markets Ltd (NOMAD & Joint Broker) Geoff Nash, Trisyia Jamaludin (Corporate Finance) Nigel Birks (Life Science Specialist Sales) Harriet Ward (ECM)
| +44 (0) 207 220 0500 |
| Shore Capital Stockbrokers Ltd (Joint Broker) David Coaten, Harry Davies-Ball (Corporate Advisory)
| +44 (0) 207 408 4090 |
| J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
| +353 (0) 1 679 6363 |
| Optimum Strategic Communications Nick Bastin, Vici Rabbetts, Elena Bates
| +44 (0) 208 078 4357 |
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
About Poolbeg Pharma plc
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. The Company's clinical programmes target large addressable markets including cancer immunotherapy-induced Cytokine Release Syndrome ("CRS") and metabolic conditions such as obesity with the development of an oral encapsulated GLP-1.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
Forward-Looking Statements
This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.